Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabizabulin Monotherapy vs Active Control in ER+HER2- MBC
NCT05079360Phase 2Withdrawn
- Sponsor
- Veru Inc.
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sabizabulin in breast cancer, sponsored by Veru Inc.. Planned start Mar 2023; status: withdrawn.
02
Drugs
sabizabulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05079360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079360.